Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 5, 2025
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 5, 2025
Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced …
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
August 5, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend …
InspireMD Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
--- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced …
Vireo Growth Inc. to Release Second Quarter 2025 Results on August 13, 2025
GlobeNewswire
·
August 5, 2025
MINNEAPOLIS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its second fiscal quarter ended June 30, 2025 on Wednesday, August 13, …
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
August 5, 2025
Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025 Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913 All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the …
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 5, 2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on- …
electroCore Appoints James C. Theofilos to the Board of Directors
GlobeNewswire
·
August 5, 2025
ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective August 1, …
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire
·
August 5, 2025
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech …
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints On track to share pivotal trial results from PEAK …
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
GlobeNewswire
·
August 5, 2025
SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and …
Bionano Announces Upgrades to its Software and Compute Platforms to Make Analysis of OGM, Microarray and NGS Data Easier, Faster and More Accurate
GlobeNewswire
·
August 5, 2025
VIA™ 7.2 transforms the workflow for optical genome mapping (OGM) data analysis with AI in constitutional genetic disorders VIA 7.2 supercharges the OGM heme workflow by allowing AI to utilize a lab’s historical results to speed future interpretations VIA …
NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors
GlobeNewswire
·
August 5, 2025
LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer …
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
GlobeNewswire
·
August 5, 2025
All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well tolerated Company expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this year Lack of approved norovirus treatments or vaccines …
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
GlobeNewswire
·
August 5, 2025
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today …
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 5, 2025
NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminent Strengthened …
Phytosterols Market Set to Hit $1.6 Billion by 2028: What’s Driving the Growth?
GlobeNewswire
·
August 5, 2025
Delray Beach, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets, the global phytosterols market is poised for significant growth, projected to rise from USD 1.0 billion in 2023 to USD 1.6 billion by 2028 at a CAGR of 8.3 percent. With …
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
GlobeNewswire
·
August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 5, 2025
- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company …
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
GlobeNewswire
·
August 5, 2025
GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune …
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
GlobeNewswire
·
August 5, 2025
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a …